Did Your GLP-1 Stop Working? Appetite, Receptors and Weight-Loss Plateaus
Summary
Host John Garrett debunks the myth of GLP-1 receptor desensitization, explaining that weight plateaus stem from metabolic adaptation rather than damaged receptors. He compares semaglutide, tirzepatide, and investigational retatrutide, clarifying that switching drugs changes pharmacology, not receptor health. The episode advises against unproven "reset" breaks and emphasizes holistic clinical reviews for managing weight loss stalls.
Topics discussed
Introduction: The myth of GLP-1 receptor desensitization
Receptor biology: Internalization vs. permanent damage
Metabolic adaptation and why weight loss plateaus occur
Tachyphylaxis: Gastric emptying adaptation vs. total failure
Semaglutide data: Sustained weight loss despite flattening curves
Tirzepatide vs. Semaglutide: Switching drugs and receptor profiles
Retatrutide: Investigational data and multi-receptor mechanisms
Lack of clinical tools to measure individual receptor responsiveness
The 'drug holiday' myth: Risks of stopping treatment
Real-world anecdotes vs. controlled clinical evidence
Clinical checklist for evaluating a weight loss plateau
Safety considerations: FDA approval status and side effects
Conclusion: Holistic review over receptor reset theories
Listen ad-free on Castria